Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’

Austin, Texas, United States, June 16th, 2026, FinanceWire

VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles,” reads a recent article.

“The company is building a pipeline that includes dual-targeting antibody-drug conjugates (‘ADCs’) and T-cell engagers (‘TCEs’) predominantly based on its patented BiTAC concept. This concept is designed to improve the precision, safety, and effectiveness of cancer treatments. Through its focus on potentially first-in-class conditionally active ADC and TCE platforms, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.”

To view the full article, visit https://ibn.fm/9jQnN

About VERAXA Biotech AG

VERAXA is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research and cutting-edge technology. For regular updates about VERAXA Biotech, visit www.VERAXA.com.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Contact